Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Spaced Out Follow-up in DME
NCT02032173Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Apr 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Started May 2014; status: terminated.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02032173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032173.